Product Images Oxcarbazepine

A log-rank test was conducted, resulting in a p-value of 0.0001 for the comparison between two groups under treatment with Oxcarbazepine. This statistical analysis assesses the difference in survival times or time-to-event data.*

Days from 1st dose to 1st seizure can be evaluated for a treatment group receiving Oxcarbazepine compared to a placebo group. The graph appears to show a timeline with days on the horizontal axis.*

This text provides results from a log-rank test, showing a p-value of 0.0001. It also presents a table showing "Time to exit (days)" for a treatment group labeled as "HIGH - LOW". The table includes intervals from 10 to 130 days, indicating the data analyzed in the log-rank test.*

This description provides the results of a log-rank test comparing two groups (HIGH and LOW) in terms of time to exit (in days). The test resulted in a p-value of 0.0001, indicating a statistically significant difference between the two groups.*

XLcare is a medication containing 150 mg of oxcarbazepine USP. It is a film-coated tablet commonly used to treat certain conditions. The dosage information can be found in the package insert. The tablets are manufactured for distribution by Evaric Pharmaceuticals Inc., based in Hauppauge, New York. For more details or assistance, one can contact the manufacturer at the provided phone number. Always keep this medication in a tightly closed container and out of reach of children.*

This text provides information about XLcare Oxcarbazepine Tablets, USP, in a 300 mg dosage form. The medication is intended for prescription use only, with a Medication Guide accompanying each patient's supply. The tablets are film-coated and should be stored within a specific temperature range. The manufacturer details are included with contact information for further inquiries.*